Lilly chief still scouting for M&A deals

Eli Lilly CEO John Lechleiter (photo) hasn't budged from his vow not to pursue a megamerger, as many of the pharma's rivals have done. "We are not interested in a large-deal combination," the exec said at the Sanford C. Bernstein investor conference. However, Lilly is looking for deals. And while diversity is essential, Lilly will look to expansion in areas congruent with its animal- and human-health model, which includes companion diagnostics and drug delivery technology. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.